Reclassification of serous ovarian carcinoma by a 2‐tier system

Abstract

Women with high-grade versus low-grade serous carcinoma of the ovary are 2 distinct patient populations. Adoption of the 2-tier grading system provides a simple yet precise framework for predicting clinical outcomes.